Clinical trial NCT04997330: Evaluation of Bilateral HF-rTMS on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction
Official title: Evaluation of Bilateral HF-rTMS Over DLPFC in add-on to Usual Treatment on Abstinence in Alcohol Use Disorder Patients With Executive Dysfunction After Withdrawal
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Alcohol Withdrawal
Keywords: alcool
rTMS
executive
dysfunction
addiction
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2021-08-09
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: High frequency repetitive transcranial magnetic stimulation (HF-rTMS) over dorsolateral prefrontal cortex (DLPFC) could correct defective executive functions over the hyperactive reward circuit through the meso-fronto-limbic connections. The restored cortical inhibitory control over compulsive alcohol use, could improve abstinence after withdrawal. The goal of this study is to evaluate the efficacy of HF-rTMS over DLPFC in AUD patients with executive dysfunction after withdrawal.

Detailed description: PARTICIPANTS:

Participants with AUD (moderate to mild according to Alcohol Dependance Scale) with executive dysfunctions will be randomized.

DESIGN:

This study is a multicenter pilot double blind randomized controlled trial. After at least seven days of alcohol residential detoxification, executive dysfunctions's participants will be tested. 64 of them with executive dysfunctions will be randomized either in the active rTMS group or in the sham rTMS group. TMS will be performed during hospitalisation over 10 days. rTMS are proposed as an add on to the usual treatment.

INTERVENTION:

20 rTMS (twice a day) will be performed 10 consecutive working days. The target of the rTMS will be the DLPFC (left side in the morning, right side in the afternoon). During each rTMS sessions (active and sham), alcohol related pictures from the Geneva Appetitive alcohol Pictures will be presented.In the active arm, rTMS will be performed with high frequency (20hz, 1500 pulses per session, 110% of motor threshold).In the control group, sham rTMS will be performed.

Participants will be follow up to three months after the end of rTMS treatment.

Eligibility criteria: Inclusion Criteria:

* Age between 18-75 years
* Alcohol use disorder according to DSM 5, moderate to mild according to ADS
* Residential stay for alcohol detoxofication

Exclusion Criteria:

* Cognitive deficits defined by MoCA \<25 (Montreal Cognitive Assessment) performed at least 7days after alcohol detoxification and after at least 12 hours after benzodiazepine cessation
* History of cerebral stroke
* DSM-5 substance use disorders other than nicotine and alcohol
* Contraindication for rTMS :

  * Pregnancy
  * History of epilepsy or seizure
  * Cochlear implants
  * Cardiac pacemaker or intracardiac lines, or metal in the body
* Clinical history of complicated withdrawal symptoms
* History of severe head trauma followed by loss of consciousness
* Actual major depressive episode, schizophrenia according to the MINI (Mini International Neuropsychiatric Interview)
* Breastfeeding women
* Actual or history of organic failure including cirrhosis
* Absence of health insurance; or patient with AME
* Legal protection (curatorship or tutorship)
* Deprive of freedom or security measure
* No adequate mastering of the French language or no ability to consent
* Major socio-economic problem: homelessness
* No written informed consent
* Participation in another interventional study

Secondary inclusion criteria (before randomization):

- Abnormal executive function defined as at least 3 impaired measurements among 19 measurements of 7 tests (Stroop test, Wisconsin test; Trail making test, verbal fluency, 6 elements, Brixton test, Dual task Baddeley test) from the Greffex battery. Each measure will be considered as impaired if it is below 1.65 SD. The procedure and the measurement are standardized. The neuropsychological evaluation will be performed at least seven days after alcohol detoxification and after at least 12 hours after benzodiazepine cessation.

Primary outcomes:
measure: Percentage of participants with continuous complete alcohol abstinence
timeFrame: 1 month after the end of rTMS sessions
Secondary outcomes:
measure: Percentage of participants with alcohol continuous complete abstinence
timeFrame: 3 months after the end of rTMS sessions
measure: Number of cumulative abstinence days
timeFrame: 1 month after the end of rTMS sessions
measure: Number of cumulative abstinence days
timeFrame: 3 months after the end of rTMS sessions
measure: Time until the first heavy drinking days (HDD)
timeFrame: 3 months after the end of rTMS sessions
measure: Number of heavy drinking days (HDD)
timeFrame: 1 month after the end of rTMS sessions
measure: Number of heavy drinking days (HDD)
timeFrame: 3 month after the end of rTMS sessions
measure: Time to relapse
timeFrame: 3 months after the end of rTMS sessions
measure: Alcohol dependence severity assessed by the Alcohol Dependence Scale (ADS)
timeFrame: 1 month after the end of rTMS sessions
measure: Alcohol dependence severity assessed by the Alcohol Dependence Scale (ADS)
timeFrame: 3 months after the end of rTMS sessions
measure: Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
timeFrame: At the last day of rTMS sessions
measure: Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
timeFrame: at 1 month after the end of rTMS sessions
measure: Alcohol cue induced craving using the Cue induced Obsessive Compulsive Drinking Scale (OCDS)
timeFrame: at 3 months after the end of rTMS sessions
measure: Change in Alcohol cue induced craving using a Visual Analogic Scale (VAS)
timeFrame: From baseline to the last rTMS session after the end of rTMS sessions
measure: Alcohol cue induced craving using a Visual Analogic Scale (VAS)
timeFrame: At 1 month after the end of rTMS sessions
measure: Alcohol due induced craving using a Visual Analogic Scale (VAS)
timeFrame: At 3 months after the end of rTMS sessions
measure: Number of impaired measures on the Grefex batery (executive functions)
timeFrame: 1 month after the end of rTMS sessions
measure: Stroop test
timeFrame: 1 month after the end of rTMS sessions
measure: Trail making test
timeFrame: 1 month after the end of rTMS sessions
measure: Verbal fluency
timeFrame: 1 month after the end of rTMS sessions
measure: Wisconsin Test
timeFrame: 1 month after the end of rTMS sessions
measure: Brixton test
timeFrame: 1 month after the end of rTMS sessions
measure: 6 elements
timeFrame: 1 month after the end of rTMS sessions
measure: Dual task Baddeley test
timeFrame: 1 month after the end of rTMS sessions
measure: Quality of life assessed by the Quality of life Scale (AQoLS)
timeFrame: At 1 month after the end of rTMS sessions
measure: Quality of life assessed by the Quality of life Scale (AQoLS)
timeFrame: At 3 months after the end of rTMS sessions
measure: % rTMS stimulation performed with optimal stimulation parameters
timeFrame: At the end of rTMS treatment
measure: Percentage of rTMS sessions performed.
timeFrame: At the end of rTMS treatment
measure: Percentage of participants experiencing sides effect
timeFrame: 3 months at the end of rTMS treatment
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Universitaire Pitié-Salpêtrière
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Fanny LEVY, Docteur
role: PRINCIPAL_INVESTIGATOR
References: